

# **EXHIBIT F**

**MAZIE SLATER KATZ & FREEMAN, LLC**  
COUNSELLORS AT LAW  
103 Eisenhower Parkway  
Roseland, NJ 07068  
(973) 228-9898  
Fax (973) 228-0303  
[www.mazieslater.com](http://www.mazieslater.com)

David A. Mazie\*  
Adam M. Slater\*<sup>o</sup>  
Eric D. Katz\*<sup>o</sup>  
David M. Freeman  
Beth G. Baldinger  
Matthew R. Mendelsohn<sup>o</sup>

Karen G. Kelsen<sup>o</sup>  
Cheryll A. Calderon  
David M. Estes  
Adam M. Epstein<sup>o</sup>  
Michael R. Griffith<sup>o</sup>  
Matthew Tonzola  
Christopher J. Geddis

---

\*Certified by the Supreme Court of  
New Jersey as a Civil Trial Attorney

---

<sup>o</sup>Member of N.J. & N.Y. Bars

November 22, 2019

**VIA EMAIL**

[SAGoldberg@duanemorris.com](mailto:SAGoldberg@duanemorris.com)

Seth A. Goldberg, Esq.  
Duane Morris LLP  
30 South 17<sup>th</sup> Street  
Philadelphia, Pennsylvania 19103-4196

**RE: *In re Valsartan Products Liability Litigation*, No. 1:19-md-02875  
Plaintiffs' Preliminary Custodian List**

Dear Counsel:

Plaintiffs are in receipt of your November 14, 2019, letter. As a preliminary matter, Plaintiffs disagree with most of Defendant ZHP's characterizations and objections.

First, in terms of temporal scope, Plaintiffs disagree that custodians should be limited to *only* those employed by the company before the recall. ZHP's investigation into the nitrosamine contamination only started at that time, and Plaintiffs are entitled to the documents stemming from that investigation, as the core discovery productions clearly demonstrate. Additionally, the investigation is ongoing. Plaintiffs cannot be prejudiced by ZHP's arbitrary cut-off of June 2018 for discovery, when employees at ZHP continue investigating the root-cause of this contamination.

Plaintiffs also disagree that subordinates are presumptively duplicative. If ZHP investigates certain custodians and their roles and finds that a superior should have received every relevant document produced or received by their subordinate, then Plaintiffs will consider the plausibility of that claim and consider removing the subordinate. Until then, Plaintiffs believe that subordinates could play an important role in this case, as subordinates very likely had more direct and detailed knowledge of the facts underlying Plaintiffs' claims.

Seth A. Goldberg, Esq.  
Duane Morris LLP  
November 22, 2019  
Page 2

Furthermore, translators are also important custodians. Not only are ZHP's translators the authors of the English language translated documents provided to regulatory agencies, they also appear to be *key factual witnesses*. For example, ZHP Translator Wei Cheng as "present for the entirety" of the FDA's May 2017 inspection and "provided all necessary translation contained within" the FDA's Report *See* PRINSTON0074146. Even more critically important, Mr. Cheng appeared to be provided his own information and observations to the FDA. *Id.* at 7 ("Mr. Cheng stated that the firm has not reworked or rejected US API since the previous US FDA inspection..."), *id.* at 21 ("Mr. Cheng explained that an SOP does not define the maintenance of that gasket"), *id.* at 22 ("Mr. Cheng had explained this change control as requiring the facilities to be updated due to production demands...").

Nevertheless, and in the spirit of continuing to meet-and-confer on these custodians, Plaintiffs have withdrawn twenty-two formerly proposed custodians, which are listed in a separate enclosed document for your reference. Plaintiffs have also included some additional custodians, which became known to Plaintiffs only upon receipt of ZHP's partially translated organizational charts.<sup>1</sup> Plaintiffs' requests, qualifications, and reservations from their November 12, 2019 letter also apply to this amended list.

In order to streamline the meet-and-confer process, Plaintiffs ask ZHP to provide Plaintiffs, in writing, with a full and complete list of those custodians ZHP will agree to provide, and those custodians for which there is still dispute.<sup>2</sup> Plaintiffs also request that ZHP provide explanation as to why certain custodians are improper and why. Indeed, this is precisely what other Defendants have done in the course of their respective meet-and-confer processes. After receiving some affirmative explanation, Plaintiffs will consider removing additional custodians.

Very truly yours,



ADAM M. SLATER

Cc: Jessica Priselac, Esq.

---

<sup>1</sup> Plaintiffs expect to receive a complete translation of the organization charts in time to meaningfully discuss them during the Parties' November 22, 2019 teleconference.

<sup>2</sup> Plaintiffs also reiterate their email of November 21, 2019, asking for proposed custodians related to finished dose quality assurance and testing functions at their Xunqiao facility,

<b>Plaintiffs' Preliminary List of Custodians for ZHP and Its Subsidiaries a</b>					
First name	Last name	Title	Department	Co.	Proffered by
<b>Senior Management</b>					
Jun	Du	Vice President of ZHP, CEO of Huahai US, Princeton, Solco, and PrinJohnson		See Title Cell	P - 10.8.19
Baohua	Chen	Chairman and General Manager		ZHP and PrinJohnson	P - 11.12.19
<b>Analytical</b>					
Xie	Chaojun		Analyst	ZHP	P - 10.8.19
Min	Li	VP	Analytical Operations	ZHP	D - 9.23.19
Minfa	Wang	VP	Analytical Operations	ZHP/Princeton	P - 10.8.19
Qing	Wang			ZHP	P - 10.8.19
Dachuan	Zhao	VP	Analytical, Shanghai R&D Center	ZHP	P - 11.12.19
Xin	Geng	Post Doctoral Fellow and Research Scientist		Hauahai US	P - 11.12.19
Jack	Guan	Senior Director Analytical Operations		Princeton	P - 11.12.19

XiaXia	Zhang	Analytical and Testing Department Manager	Chuannan Branch Analytical Center	ZHP	New
Jun	Wang	Finished Dose Gase Stage Team	Chuannan Branch Analytical Center	ZHP	New
Chun	Yang	Finished Dose Liquid Phase Team	Chuannan Branch Analytical Center	ZHP	New
Guang	Zheng	Raw Material Central Control Instrument Team	Chuannan Branch Analytical Center	ZHP	New
XianLiang	Zhang	Raw Material Central Control Physico-Chemical Team	Chuannan Branch Analytical Center	ZHP	New
Yun	Jin		Chuannan Branch Analytical Center	ZHP	New
<b>Quality</b>					
Wei	Cheng	VP	API Quality Assurance	ZHP	P - 10.8.19
Remonda	Gergis	VP	Quality Assurance	Prinston	P - 10.8.19
Zheng	Youqing	Deputy Manager	Quality Assurance	ZHP	P - 10.8.19
Jucui	Ge	Director	Quality Assurance (API Division)	ZHP	D - 9.23.19
Yuelin	Hu	Assistant Director	Quality Assurance (API Division)	ZHP	D - 10.7.19
Ziqiang	Gu	Independent Consultant		ZHP and Prinston	P - 10.8.19

Xiaohong	Zhao	Director	Quality Assurance (Chuannan Site)	ZHP	P - 10.8.19
Hongliang	Wang		Quality	ZHP	P - 11.12.19
Zhen	Ye		Quality	ZHP	P - 11.12.19
Baozhen	Chen	Director	Corporate Quality Assurance	ZHP	P - 11.12.19
Cunxiao	Ye	Vice President	Quality Assurance, Headquarters	ZHP	P - 11.12.19
Caifeng	Zhao	Manager	Quality Assurance	ZHP	P - 11.12.19
Dongqin	Wang	Assistant Director	Quality Assurance at Chuannan Site East Zone	ZHP	P - 11.12.19
Zhizhang	Ding	Assistant Manager	Formulation Quality Assurance	ZHP	P - 11.12.19
Y.F.	Chen	Senior Supervisor	API Quality Assurance	ZHP	P - 11.12.19
Xiong	Fei	Analyst	Quality Control	ZHP	P - 10.8.19
Hu	Guangping	Director	Quality Control	ZHP	P - 10.8.19

Huang	Rui	Director	Quality Control	ZHP	P - 10.8.19
Minli	Zhang	Director	Finished Dose Quality Assurance and Quality Control	ZHP	D - 10.16.19
Qiangming	Li	Director	Quality Control (API Division)	ZHP	D - 9.23.19
Zie	Chaojun	Analyst	Quality Control	ZHP	P - 10.8.19
Quang	Zhou	Analyst	Quality Research	ZHP	D - 10.23.19
Ying	Xiong	Supervisor	Quality Research	ZHP	D - 10.23.19
Fong E.	Zhuong	Associate Manager	Quality Research	ZHP	Discussed but not agreed to on 10.23.19
Dan Ping	Cai	Technical Assistant Director	Quality Research	ZHP	Discussed but not agreed to on 10.23.19
Yuanyan	Chen	Supervisor	Quality Research	ZHP	Discussed but not agreed to on 10.23.19
Yinhua	Tang	Assistant Director/Manager	Quality Control	ZHP	P - 11.12.19
Fei	Shang	QP	Quality VP	ZHP	P - 11.12.19
Yun	Jin	Supervisor	Chuannan Quality Control	ZHP	P - 11.12.19

Tian	Zhang	Analyst	Chuannan Q Control	ZHP	P - 11.12.19
Xianhua	Zhang	Deputy Director	Chuannan Quality Control	ZHP	P - 11.12.19
Yuping	Chen	Deputy Manager	Formulation Quality Control	ZHP	P - 11.12.19
Xiaoling	Li	Manager	Formulation Quality Control	ZHP	P - 11.12.19
Qiang	Zhuo	Analyst	API Quality Research	ZHP	P - 11.12.19
Tong	Wu	Analyst	API Quality Research	ZHP	P - 11.12.19



Tan	Xiao	Senior Supervisor	API Quality Research	ZHP	P - 11.12.19
Wenbin	Chen	Analysis Director	API Quality Research	ZHP	P - 11.12.19
Nan	Tong	Senior Supervisor	API Quality Research	ZHP	P - 11.12.19
Wenping	Hu	Team Leader	Quality Research	ZHP	P - 11.12.19
Wenquan	Zhu	Director	API Quality Research	ZHP	D- 10.16.19

X. G.	Liu	Quality Researcher	API Quality Research	ZHP	P - 11.12.19
Y.Y.	He	Quality Researcher	API Quality Research	ZHP	P - 11.12.19
Ye	Jenson		QP	ZHP	P - 11.12.19
Jieyun	Wang	Director	Quality Assurance	ZHP	New
Ting	Sung	Manager	Quality Control	ZHP	New
Jian	Ye	Deputy Manager, Group I	Quality Control	ZHP	New
Houming	Zhou	General Detection, Technical Deputy Director	API Quality Study/Research Department	ZHP	New
Xiao	Yu	Associate Director	API Quality Study/Research Department	ZHP	New
Yang	Han	Supervisor	Quality Research	ZHP	New
Chaohua	Bao	Supervisor	API QR	ZHP	New
<b>Manufacturing</b>					
Xiamong	Liu	Head	Technical for Finished Dose	ZHP	D - 10.16.19
Congsheng	Jin	Valsartan Workshop Director		ZHP	P - 11.12.19
Yongjun	Jin	Factor Assistant Director	Manufacturing	ZHP	P - 11.12.19

Dong	Peng	Director	Technical Department	ZHP	D - 9.23.19
Peng	Wang	Senior Director	API Manufacturing	ZHP	D - 9.23.19
Youhu	Wang	Technology Leader		ZHP	P - 11.12.19
Jiangzhong	Yu	API and Intermediate Plant Manager	Manufacturing	ZHP	P - 11.12.19
Wenling	Zhang	Director Assistant	Technical, API Chuannan site West Zone (counterpart to Peng Dong)	ZHP	P - 11.12.19
Lijin	Jiang	VP	API Operation/Facility Director, API Chuannan Site	ZHP	P - 11.12.19
Zhengjun	Jia	Deputy Plant Director	Engineering and Maintenance, API Chuannan site East Zone	ZHP	P - 11.12.19
Junhui	Zuo	Deputy Plant Director	Engineering and Maintenance, API Chuannan site West Zone	ZHP	P - 11.12.19
Wei	Chen	Deputy Director	Production Department	ZHP	P - 11.12.19
Lina	Wu	Senior Supervisor	Formulation Technology at ZHP	ZHP	P - 11.12.19
Xiaoming	Liu	Director	Formulation Technology at ZHP	ZHP	P - 11.12.19

Eric Wen-Chien	Tsai, PhD	General Manager		Princeton and Prinbury BioPharm	P - 11.12.19
Pieter	Groenewoud	Executive Director	Technology	ZHP	P - 11.12.19
Chunmin	Xu	Vice President		ZHP	New
Hu	Zhou	Factory Director		ZHP	New
Ruqi	Zhou	Factory Assistant Director		ZHP	New
Kaai	Yang	Technical Manager		ZHP	New
Ruping	Ren	Auxiliary Workshop Director		ZHP	New
Yanhua	Meng	General Manager	Chuannan Product Technical Center	ZHP	New
Fengfeng	Yan	Director of Tech	Chuannan Product Technical Center	ZHP	New
Zunjun	Liang	Associate Director	Chuannan Product Technical Center	ZHP	New

Zhichen	Hu	Manager	Chuannan Product Technical Center	ZHP	New
Xiauhui	Zhan	"(Valsartan)"	Chuannan Product Technical Center	ZHP	New
Mengmeng	Xie	General Supporting Group	Chuannan Product Technical Center	ZHP	New
<b>Regulatory</b>					
Linhong (Linda)	Lin	Director	Regulatory Affairs Department	ZHP	D - 9.23.19
Wei	Chen	Translator		ZHP	P - 11.12.19
Zhi	Chen			Huahai US	P - 10.8.19
Yanfeng (Lucy)	Liu	Deputy Director / Manager	Regulatory Affairs	ZHP	D - 10.7.19
Lije	Wang	VP	Head of Regulatory Affairs	Princeton	P - 10.8.19
Ying	Xiong	Supervisor	Regulatory Affairs	ZHP	D 10.16.19
Quo (Kathy)	Zhang	Senior Manager	Regulatory Affairs	Huahai US	P – 10.8.19
Xiaodi	Guo	Vice President		Huahai US (linkedin), Princeton (website), and Solco (affidavits of service)	P for Princeton/Huah ai US - 10.8.19 / Solco - 11.12.19
Wei (Helen)	Tong	Director	Regulatory Affairs	ZHP and Princeton?	P - 11.12.19
Ting (Ada)	Zhou	Assistant Director	Regulatory Affairs	ZHP	D - 10.7.19
Louis	Zhao		Regulatory Affairs	Princeton	P - 11.12.19

Guangyu	Luo	Associate (2013-2015), Senior Associate (2015-2016), Specialist (2016-2017), Manager (2017-Present)		Princeton	P - 11.12.19
Jenny	Lu	Senior Associate	Regulatory Affairs	Princeton	P - 11.12.19
Yuding	Zhao	Director	Finished Dose RA	ZHP	D - 10.23.19
Yiming	Tang				New
Deng Xue	Sung	Manager	API R&D, Regulation Affairs	ZHP	New
Jie	Lin	Deputy Manager	API Patent, Regulation Affairs	ZHP	New
<b>Procurement</b>					
Min	Hu		Purchasing	ZHP	D - 10.16.19
Weiwei	Xu		Purchasing	ZHP	D - 10.16.19
Min	Xu		Purchasing	ZHP	D - 10.16.19
Min	Xang		Procurement	ZHP	D - 10.16.19
Zheng	Gaozhe		Purchasing	ZHP	D - 10.16.19
<b>API Sales</b>					
Minda	Cai	Former VP	API Sales	ZHP	D - 10.16.19
Jie	Wang	VP	Business Development	ZHP	D - 9.23.19
Sheng	Zhong	Director	Business Development	ZHP	D - 10.16.19
Wei	Chang	Translator	Business Development, API Sales	ZHP	D - 10.23.19
Hongchao	Li	Manager	Business Development	ZHP	D - 10.16.19
Xu	Mi		Business Development, API Sales	ZHP	D - 10.16.19

Weihua Wang	Wang	Vice President	Sales	ZHP	New
Lei	Li	"Brand Customer"	Sales	ZHP	New
Zengyuan (sp?)		"Customer Service"	Sales	ZHP	New
<b>Other Sales</b>					
John	Iozzia	Director	Sales	Huahai US	D - 10.16.19
Chris	Keith	Director	Sales	Solco/Prinston at some point as VP	D - 10.22.19 for Solco / Prinston - 11.12.19
Lesley	Zhu	SVP, Business Development & Portfolio	Sales	Prinston	P - 10.8.19
Hai	Wang	VP, President, President		Huahai US (linkedin), Prinston (website), & Solco (website), respectively	P for Solco - 10.8.19
Min	Hu	Manager of Business Development and Senior Director of Business Development		Huahai US (2007-2012) and Prinston (2012-Present), respectively	P - 11.12.19
David	Ayres	Vice President	Sales	Solco	P - 11.12.19
Xin (Will)	He	Scientist (2012-2016), Manager (2019-Present)		Prinston	P - 11.12.19
Peng	Shang	Senior Associate of Business Development/ Supply Chain		Prinston	P - 11.12.19

Matthew	Arnold	National Account Manager from 2016-2019		Solco	P - 11.12.19
<b>Syncores</b>					
Eric	Gu	Manager		Shanghai Syncores	P - 10.8.19
James (Jun)	Wen	President		Shanghai Syncores	P - 11.12.19
Frank	Zhao	VP		Shanghai Syncores	P - 11.12.19
<b>Prinbury BioPharm Ltd.</b>					
Wenjian	Cai	General Manager		Prinbury	P - 11.12.19
Dachuan	Zhao	Executive Deputy General Manager		Prinbury	P - 11.12.19
Ping	Wen	Executive Director		Prinbury	P - 11.12.19
Yuanyuan	Xie	Director	Pharmaceutical Affairs	Prinbury	P - 11.12.19
Li	Tan	Director	Project Management	Prinbury	P - 11.12.19
Wei	Tian	Deputy General Manager of Analysis and Research		Prinbury	P - 11.12.19
Hongchun	Qiu	Deputy General Manager of Pharmaceutical Preparation Product Development		Prinbury	P - 11.12.19
Shine	Chen	Scientist		Prinbury	P - 11.12.19
Tina	Liu	Senior Scientist		Prinbury	P - 11.12.19



Yun	Tian	Senior Director		Prinbury	P - 11.12.19
Lily	Tan	QA Manager		Prinbury	P - 11.12.19
Alex	Liu	Scientist		Prinbury	P - 11.12.19
Ashley	Lin	Associate Scientist		Prinbury	P - 11.12.19
Yula	Wang	Executive Director		Prinbury	P - 11.12.19
<b>Consultants</b>					
Derek	Zhang, PhD			Alavanda Regulatory & Drug Development Consulting, Inc. (Regulatory Consultant for Princeton Pharmaceutical Inc.)	D - 10.23.19
Dylan	Yao, Ph.D.	Chief Scientific Officer & Senior Vice President		Jonn Laboratories Inc. (Consultant for Princeton Pharmaceutical Inc.)	D - 10.23.19
Charles	Wang	VP of Drug Safety and DMPK		Consultant from InnoCare Pharma, Inc. for ZHP	D 10.23.19
Douglas	Campbell	Consultant		ZHP	New

s of 11/22/2019
Explanation
PrinJohnson's Facebook Identifies Du as its CEO
His senior role in the investigation of the Valsartan contamination. PrinJohnson's Facebook identifies him as its CEO.
Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
"Expertise in various purification techniques including chromatography, recrystallization, and distillation" -LinkedIn
"A pharmaceutical professional with strong expertise in analytical R&D, Quality Control, Pre-formulation, Quality Assurance, Compliance and Regulatory Affairs. Proven track records of leading operations and activities in analytical R&D, quality units, health authority inspections, and project management." -LinkedIn



Prepared Method Validation Report of Valsartan PRINSTON00031401
Reviewed part of Method Validation Report of Valsartan PRINSTON00031402
Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Prepared Deviation Investigation Report of Valsartan TEA Process V1, 2, & 3 PRINSTON0073443, 0075797, 0076100
Reviewed and signed off on Deviation Investigation Report of Valsartan TEA Process V1, 2, & 3 PRINSTON0073443, 0075797, 0076100; attended 5.19.17 meeting after the FDA inspection PRINSTON0074159
Reviewed and approved Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384
Reviewed and approved Validation Report of LC-MS Method for NDBA in Losartan Potassium PRINSTON0074642; ; reviewed and approved the Validation Report of LC-MS Method for NMBA in Irbesartan PRINSTON0074712

Org Chart
Org Chart
Org Chart
Reviewed and signed off on Deviation Investigation Reports of Valsartan TEA Process PRINSTON0073443, etc.; attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Reviewed and approved the third version of the Deviation Investigation into the TEA process PRINSTON0076100
Drafted Assay Method Validation Report for Valsartan (Supplement) PRINSTON00009948; draft Chiral Purity Analytical Method Validation Protocol for TDCI Compound PRINSTON00077405

Reviewed and signed off on Assay Method Validation Report for Valsartan (Supplement) PRINSTON00009948; reviewed and signed off on Chiral Purity Analytical Method Validation Protocol for TDCI Compound PRINSTON00077405

Reviewed and signed off on Assay Method Validation Report for Valsartan (Supplement) PRINSTON00009948; reviewed and signed off on Chiral Purity Analytical Method Validation Protocol for TDCI Compound PRINSTON00077405

Author of Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384

Reviewed and signed off on Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384

Drafted Validation Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326

Drafted Validation Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326

Drafted Validation Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326; reviewed and approved Validation report of the LC-MS method for NDMA in Losartan Potassium PRINSTON0074642; reviewed and approved the Validation Report of LC-MS Method for NMBA in Irbesartan PRINSTON0074712

Reviewed and signed off on Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326; ; reviewed and approved the Validation Report of LC-MS Method for NMBA in Irbesartan PRINSTON0074712

Approved the cGMP compliance for its intended use of Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326

Reviewed data in Hydrochlorothiazide Residual Solvent Method Validation Report PRINSTON00064288; Reviewed Comparison of Valsartan USP Method and In-house Method for Integrity and Correctness PRINSTON00064389

Drafted Validation report of the LC-MS method for NDBA in Losartan Potassium PRINSTON0074642
Drafted Validation Report of LC-MS Method for NMBA in Irbesartan PRINSTON0074712
Approved the Deviation Investigation Reports of Valsartan TEA Process PRINSTON0073443, etc.
PRINSTON00077850
Org Chart
Org Chart
Org Chart
Org Chart
Org Chart
Org Chart
Prepared Comparison of Valsartan USP Method and In-house Method PRINSTON00064389
Identified as the person “responsible for production of Valsartan”
Described as a “professional engineer,” and “has a wide experience at production technology management and is responsible for the technological development of all bulk drugs”



“Is responsible for Valsartan”
Responsible for all bulk drugs (including intermediates) at ZHP
Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Reviewed and approved Deviation Investigation Reports regarding the TEA Process PRINSTON0073443, 0075797, 0076100
Author of Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384
Reviewed and signed off on Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384

Authorized signatory and sponsor  
or Quality Assurance  
Authentication of Valsartan.  
PRINSTON00029811. "Eric joined  
Prinbury BioPharm as General  
Manager in 2009, wholly owned  
subsidiary of Prinston, a Research  
and Development center located in  
Shanghai China. In this role he  
leads the R&D efforts has been  
making significant contribution to  
Prinston pipeline growth. Eric  
came to the company with strong  
technical expertise and  
management skills." -Prinston  
Website

Reviewed Master Packaging  
Record Approval  
PRINSTON00021688

PRINSTON00070584, 79392

PRINSTON00070586

PRINSTON00070587, 79392

PRINSTON00070587, 79392

PRINSTON00077851

Org Chart

Org Chart

Org Chart

Org Chart
Org Chart
Org Chart
Translatered 08/26/2018 Ltr to the FDA
He has accepted service as Solco's VP.
Listed on ANDA Documents
Linkedin

"Regulatory Affairs, mainly on regulatory submissions (from draft to e-CTD compilation), pharmacovigilance (AE handling and submission) and generic labeling (content, artwork and SPL)." -Linkedin
Linkedin
Contact Person for ZHP's U.S. Agent PRINSTON0076915
Org Chart
Org Chart
Was a person who was responsible for procuring solvents

Org Chart
Org Chart
Org Chart
Solco's Website
Linkedin
Solco's Website
"Working at formulation position of Product Development Department." -Linkedin
Linkedin

Linkedin and Author of Only Solco-stamped document
Linkedin
Linkedin
Prinbury website
Prinbury website
Prinbury website
Prinbury website
Prinbury website
Prinbury website
Prinbury website
Prepared Method Verification Report for Valsartan PRINSTON00039715
Reviewed Method Verification Report for Valsartan PRINSTON00039715

Approved Method Verification Report for Valsartan PRINSTON00039715
Approved Method Verification Report for Valsartan PRINSTON00039715
Prepared Dissolution Comparison Study Report of Valsartan PRINSTON00050114
Prepared Method Robustness Study Report for Valsartan PRINSTON0039541
Reviewed and approved Master Production Batch Record Approval PRINSTON00064070
Email PRINSTON00070408

<b>Plaintiffs' List of Withdrawn Custodians for ZHP and Its Subsidiaries as of 11/22/2019</b>				
First name	Last name	Title	Department	Co.
Juan	Tao	Director Assistant	Quality Assurance	ZHP
Xiaofen	Zhu	Analyst	Quality Control	ZHP
Hui	Dai	Analyst	Quality Control	ZHP
Jing	Jin	Deputy Manager	Quality Control	ZHP
J. Y.	Li	Analyst	Quality Control	ZHP
J.	Wang	Analyst	Quality Control	ZHP
Yingzhi	Chen	Analyst	Quality Control	ZHP
Chongjun	Xie	Analyst	Quality Research	ZHP
Jon M.	Bill, Jr.	VP & General Manager		Princeton Laboratories
Shuxi	Li	Technician	Formulation Technology at ZHP	ZHP
Pijie	Xu	Assistant Director	Formulation Manufacture	ZHP
Weildin g	Bian	Director	Formulation Manufacture	ZHP
Xiaojun	Gao	Technician	Technology	ZHP
Zho	Cheng		Business Development	ZHP
Frank	Chen	Chief Investment Officer of Huahai US and CFO of PrinJohnson (according to PrinJohnson's Facebook)		Huahai US and PrinJohnson
Ping	Jiang	CFO (2015-2016)		PrinJohnson



Jane Qiu	X.	Senior Manager, Strategic Sourcing & Project Management		Prinston
Mark	Pierce	National Account Manager as of September 2019		Solco
Alan Huashen g	Ding	Director	Business Development	Shanghai Syncores
Luping	Liu	Vice President		Shanghai Syncores
Luke	Wang			Prinbury
Jihui	Wang	Technician		Prinbury